Via Pharmaceuticals Inc. (VIAP)

Overview

VIA Pharmaceuticals, Inc. represents a pioneering force in the biotechnology sector, primarily focusing on the advancement of novel therapies aimed at cardiovascular and metabolic illness intervention. Operating from its inception in 2004, the company has dedicated itself to the formulation of small molecule drugs designed to tackle the root causes of various cardiovascular and metabolic disorders. Such conditions include, but are not limited to, vascular inflammation, abnormal cholesterol levels, insulin resistance/diabetes, and increased triglycerides. With its headquarters in San Francisco, California, VIA Pharmaceuticals stands as a beacon of innovation in the development stage of the biotech industry. Additionally, the company boasts strategic research, development, and commercialization collaborations with esteemed entities such as Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd., particularly concerning its THR beta agonist and DGAT1 metabolic disorders program.

Products and Services

• VIA-3196: This liver-targeted thyroid hormone receptor (THR) beta agonist is poised at the Phase-1 readiness stage, specifically designed to address dyslipidemia conditions such as high LDL cholesterol, elevated triglycerides, and raised Lp(a) levels.

  VIA-3196 leverages the therapeutic potential of modulating thyroid hormone receptors to restore lipid metabolism balance, thus mitigating the risk factors associated with cardiovascular diseases.

• DGAT1 Inhibitor: Currently in the pre-clinical development stage, this compound represents VIA Pharmaceuticals' venture into the treatment of type 2 diabetes, with a promising outlook for weight management and dyslipidemia.

  The inhibitor targets Diacylglycerol Acyl Transferase 1 (DGAT1), a critical enzyme in triglyceride synthesis and energy metabolism, offering a novel approach to controlling blood sugar levels and aiding in weight loss.

• VIA-2291: As a 5-Lipoxygenase inhibitor, VIA-2291 has successfully completed its third Phase 2 clinical trial, targeting the reduction of atherosclerotic plaque. This accumulation of plaque is a primary contributor to heart attacks, strokes, and various vascular diseases.

  By inhibiting the 5-Lipoxygenase pathway, VIA-2291 aims to decrease inflammation and oxidative stress within the arterial walls, thus reducing the buildup of atherosclerotic plaque and lowering the risk of cardiovascular events.